Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT06149481 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Retifanlimab
BIOLOGICAL: Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
DRUG: N-803
DRUG: SX-682

Sponsor

National Cancer Institute (NCI)